ELacestrant

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 108 publications

Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title.

Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title.

Journal: Expert opinion on pharmacotherapy

Published: May 22, 2026

ESR1 mutations in ER-positive breast cancer: from endocrine resistance to ctDNA-guided therapeutic interception.

ESR1 mutations in ER-positive breast cancer: from endocrine resistance to ctDNA-guided therapeutic interception.

Journal: Exploration of targeted anti-tumor therapy

Published: January 28, 2026

Imlunestrant (Inluriyo) for advanced breast cancer.

Imlunestrant (Inluriyo) for advanced breast cancer.

Journal: The Medical letter on drugs and therapeutics

Published: January 08, 2026

Elacestrant in metastatic breast cancer: current advancements and future perspectives.

Elacestrant in metastatic breast cancer: current advancements and future perspectives.

Journal: Expert review of anticancer therapy

Published: December 29, 2025

Standardized Analytical Verification of ctDNA ESR1 Mutation Testing in Metastatic HR+/HER2- Breast Cancer: A European Multicentre Study Using dPCR and NGS-Based Liquid Biopsy.

Standardized Analytical Verification of ctDNA ESR1 Mutation Testing in Metastatic HR+/HER2- Breast Cancer: A European Multicentre Study Using dPCR and NGS-Based Liquid Biopsy.

Journal: Molecular diagnosis & therapy

Published: December 22, 2025

Real-world evidence for 10 oncology drugs approved in the last 5 years: A comprehensive narrative synthesis.

Real-world evidence for 10 oncology drugs approved in the last 5 years: A comprehensive narrative synthesis.

Journal: Critical reviews in oncology/hematology

Published: December 08, 2025

Real-World Evidence for 10 Oncology Drugs Approved in the last 5 years: A Comprehensive Narrative Synthesis.

Real-World Evidence for 10 Oncology Drugs Approved in the last 5 years: A Comprehensive Narrative Synthesis.

Journal: Critical reviews in oncology/hematology

Published: December 08, 2025

Characterization of In Vitro Metabolic Profiles of Elacestrant in Rat and Human Liver Microsomes Using HPLC-MS/MS and HPLC-Q-Orbitrap-HRMS.

Characterization of In Vitro Metabolic Profiles of Elacestrant in Rat and Human Liver Microsomes Using HPLC-MS/MS and HPLC-Q-Orbitrap-HRMS.

Journal: Biomedical chromatography : BMC

Published: December 02, 2025

Efficacy and safety of treatments in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor progression: a network meta-analysis and scoping review.

Efficacy and safety of treatments in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor progression: a network meta-analysis and scoping review.

Journal: BMC cancer

Published: September 19, 2025

Protacs Targeting ERα in the Effective Management of Endocrinal Resistance Breast Cancer.

Protacs Targeting ERα in the Effective Management of Endocrinal Resistance Breast Cancer.

Journal: Archiv der Pharmazie

Published: September 11, 2025

Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.

Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 13, 2025

Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.

Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 13, 2025

Showing 1-12 of 108

Last Updated: 06/30/2026